Cargando…

Updated risk assessment concerning the risk to wild mammals for the active substance gamma‐cyhalothrin

The risk assessment for gamma‐cyhalothrin in light of confirmatory data requested following approval in accordance with Article 6(1) of Directive 91/414/EEC and Article 6(f) of Regulation (EC) No 1107/2009 concluded that the long‐term risk to wild mammals from the proposed representative uses of gam...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985835/
https://www.ncbi.nlm.nih.gov/pubmed/33777237
http://dx.doi.org/10.2903/j.efsa.2021.6489
_version_ 1783668328128053248
collection PubMed
description The risk assessment for gamma‐cyhalothrin in light of confirmatory data requested following approval in accordance with Article 6(1) of Directive 91/414/EEC and Article 6(f) of Regulation (EC) No 1107/2009 concluded that the long‐term risk to wild mammals from the proposed representative uses of gamma‐cyhalothrin was not fully addressed. Following further considerations during the decision‐making process, the European Commission asked EFSA to update the risk assessment for wild mammals and consider a restriction to the proposed good agricultural practice (GAP). The outcome of the updated peer review of the risk assessment for wild mammals is presented.
format Online
Article
Text
id pubmed-7985835
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-79858352021-03-25 Updated risk assessment concerning the risk to wild mammals for the active substance gamma‐cyhalothrin EFSA J Statement The risk assessment for gamma‐cyhalothrin in light of confirmatory data requested following approval in accordance with Article 6(1) of Directive 91/414/EEC and Article 6(f) of Regulation (EC) No 1107/2009 concluded that the long‐term risk to wild mammals from the proposed representative uses of gamma‐cyhalothrin was not fully addressed. Following further considerations during the decision‐making process, the European Commission asked EFSA to update the risk assessment for wild mammals and consider a restriction to the proposed good agricultural practice (GAP). The outcome of the updated peer review of the risk assessment for wild mammals is presented. John Wiley and Sons Inc. 2021-03-23 /pmc/articles/PMC7985835/ /pubmed/33777237 http://dx.doi.org/10.2903/j.efsa.2021.6489 Text en © 2021 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made.
spellingShingle Statement
Updated risk assessment concerning the risk to wild mammals for the active substance gamma‐cyhalothrin
title Updated risk assessment concerning the risk to wild mammals for the active substance gamma‐cyhalothrin
title_full Updated risk assessment concerning the risk to wild mammals for the active substance gamma‐cyhalothrin
title_fullStr Updated risk assessment concerning the risk to wild mammals for the active substance gamma‐cyhalothrin
title_full_unstemmed Updated risk assessment concerning the risk to wild mammals for the active substance gamma‐cyhalothrin
title_short Updated risk assessment concerning the risk to wild mammals for the active substance gamma‐cyhalothrin
title_sort updated risk assessment concerning the risk to wild mammals for the active substance gamma‐cyhalothrin
topic Statement
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985835/
https://www.ncbi.nlm.nih.gov/pubmed/33777237
http://dx.doi.org/10.2903/j.efsa.2021.6489
work_keys_str_mv AT updatedriskassessmentconcerningtherisktowildmammalsfortheactivesubstancegammacyhalothrin